Scalability Considerations When Using Cord Blood as an Allogeneic Starting Material

Learn why cord blood may be an excellent starting material for your therapy Cord blood has been used to provide life-saving treatments to patients for decades, but its full potential has not yet been tapped. During this hour long on-demand webinar, our panelists discuss: Why it’s essential to have a good understanding of critical starting…

Best practices along the allogeneic product collection pathway

Considerations for developing scalable and efficient collection network processes The decisions you make when selecting apheresis centers to collect source material for your cell or gene therapy impact your ability to efficiently scale your processes. When your processes and protocols differ from those at an apheresis center, delays can occur. Following best practices can help.…

Considerations for Developing Scalable and Efficient Collection Network Processes

On-demand webinar offers actionable insights as you develop your protocols. Many crucial considerations impact a cell and gene therapy developer’s apheresis center selection strategy and ability to efficiently scale processes. When collection processes or protocols differ from those in place at a center, there are likely implications for training, forms and standard operating procedures. This…

6 Considerations When Evaluating Cell Sourcing Partners

Sourcing your starting material from healthy, high-quality donors matters when you are manufacturing an allogeneic cell therapy. Any misstep can mean delays in your therapy’s development. Keep these key considerations top of mind as you evaluate whether potential partners have the experience, expertise and relationships required to identify, source and collect your allogeneic donors and…

Strategies to Advance the Donor Selection Process for Cell Therapies to Improve Outcomes

HLA matching in the development of leading-edge allogeneic therapeutics and cellular therapies—and hematopoietic stem cell transplantation (HSCT)—isn’t only about finding the best matches. It’s also about avoiding mismatches that could result in less optimal patient outcomes. During this on-demand webinar you’ll hear from industry experts about research identifying HLA-B mismatches that are most optimal and…

Size Matters: Ensuring Donor Pool Sustainability and Cell Therapy Supply Chain Success When Scaling Up and Out

View this on-demand webinar to learn how to increase potential for long-term success in allogeneic and autologous programs. Discover the keys to enabling a smoother, faster transition to market and ultimately, access to more patients. Our expert panelists will cover: What to expect when transitioning from small trial sizes to large volumes, while also managing…